Drug Trial Radar · NCT05006716
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
689
Planned (sponsor's estimate)
Start
Sep 13, 2021
Primary completion
Mar 2027
Study completion Mar 2030
Sponsor
- Lead sponsor
- BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Aug 16, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study consists of two main parts to explore tacabrutideg recommended dosing, a Phase 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a Phase 2 (expansion cohorts)
Conditions
- B-cell Malignancy
- Marginal Zone Lymphoma
- Follicular Lymphoma
- Non-Hodgkin Lymphoma
- Waldenström Macroglobulinemia
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Mantle Cell Lymphoma
- Diffuse Large B Cell Lymphoma
- Richter Transformation
Interventions
TacabrutidegDrug
Orally administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Number of Participants with Adverse Events (AEs)Time frame: From the first dose of tacabrutideg until 30 days after the last dose of the study drug or before the initiation of a new anticancer therapy, whichever occurs first (Up to 47 weeks)
- Phase 1: Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of TacabrutidegTime frame: Approximately 28 days
- Phase 1: Recommended dose(s) for Expansion (RDFE) of tacabrutidegTime frame: Approximately 3 years
- Phase 2: Overall response rate (ORR)Time frame: approximately 3 years
Locations
114 sites in 16 countries. Site status is shown where the registry gives one.
University of Alabama At Birmingham Hospital
Birmingham, Alabama · Recruiting
Mayo Clinic Phoenix
Phoenix, Arizona · Completed
Honor Health Research Institute
Scottsdale, Arizona · Recruiting
University of Arizona Cancer Center
Tucson, Arizona · Recruiting
University of California San Diego (Ucsd) Moores Cancer Center
La Jolla, California · Recruiting
Stanford Medicine
Palo Alto, California · Recruiting
UCLA Santa Monica Cancer Care
Santa Monica, California · Recruiting
Uchealth North
Fort Collins, Colorado · Recruiting
Mayo Clinic Jacksonville
Jacksonville, Florida · Recruiting
Mount Sinai Medical Center Braman Comprehensive Cancer Center
Miami, Florida · Recruiting
Tampa General Hospital Cancer Institute
Tampa, Florida · Recruiting
Augusta University
Augusta, Georgia · Recruiting
Southeastern Regional Medical Center
Newnan, Georgia · Recruiting
Midwestern Regional Medical Center
Zion, Illinois · Completed
University of Iowa Hospitals and Clinics
Iowa City, Iowa · Recruiting
Norton Cancer Institute Pavilion
Louisville, Kentucky · Active not recruiting
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana · Recruiting
American Oncology Partners of Maryland Pa
Bethesda, Maryland · Recruiting
Dana Farber Cancer Institute
Boston, Massachusetts · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
Mayo Clinic Rochester
Rochester, Minnesota · Recruiting
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada · Recruiting
Roswell Park Comprehensive Cancer Center
Buffalo, New York · Recruiting
Columbia University Medical Center
New York, New York · Recruiting
Weill Cornell Medical College Newyork Presbyterian Hospital
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center Mskcc
New York, New York · Recruiting
Tennesse Oncology Chattanooga Downtown
Chattanooga, Tennessee · Recruiting
Tennessee Oncology, Pllc Nashville
Nashville, Tennessee · Recruiting
Md Anderson Cancer Center
Houston, Texas · Recruiting
Virginia Commonwealth University Massey Cancer Center
Richmond, Virginia · Recruiting
Fred Hutchinson Cancer Research Center
Seattle, Washington · Recruiting
Concord Repatriation General Hospital
Concord, New South Wales, Australia · Recruiting
Calvary Mater Newcastle
Waratah, New South Wales, Australia · Recruiting
Princess Alexandra Hospital
Woolloongabba, Queensland, Australia · Recruiting
St Vincents Hospital Melbourne
Fitzroy, Victoria, Australia · Recruiting
Austin Health
Heidelberg, Victoria, Australia · Recruiting
Peter Maccallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
The Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
Linear Clinical Research
Nedlands, Western Australia, Australia · Recruiting
Perth Blood Institute
West Perth, Western Australia, Australia · Recruiting
Showing 40 of 114 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.